Window Therapeutics, Inc.
- Industry
- Biotechnology
- Founded Year
- 2020
- Headquarters
- 100 William T Morrissey Blvd, Dorchester, MA 02125
- Employee Count
- 3
Key People
- Walter Capone - Chief Executive Officer
- Chih-Kao Hu - Interim CEO and Director
- Kenneth C. Anderson, MD - Director
- James Lu, MBA, JD - Director
- Raju Kucherlapati, PhD - Advisor
- Yivan Jiang, PhD - Co-Founder & Director of Manufacturing Development
- Hung Nguyen, PhD - Co-Founder & Director of Therapeutics Development
- Jeremiah Johnson, PhD - Co-Founder, Board Member and Chairman of Scientific Advisory
- Lawrence Dick, PhD - Advisor
- Sanjana Hemdev, MS - Associate Scientist
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises individuals with extensive experience in biotechnology and therapeutic development.
The presence of seasoned professionals in key roles suggests a strong foundation for the company's strategic and operational initiatives.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's focus on developing therapeutics for cancer addresses a critical unmet need in the medical field.
Cancer remains a leading cause of mortality worldwide, and innovative treatments are in high demand, providing a substantial market opportunity.
- Competition
-
Aspect: Very crowded + Strategics
Summary: The oncology therapeutics market is highly competitive with numerous established players.
The presence of numerous competitors, including large pharmaceutical companies, necessitates unique value propositions to capture market share.
- Technical Challenge
-
Aspect: Complex
Summary: Developing novel cancer therapeutics involves significant technical complexities.
The intricate nature of cancer biology and the need for targeted therapies present substantial challenges in research and development.
- Patent
-
Aspect: Applied
Summary: The company has applied for patents related to its proprietary technology.
Intellectual property protection is vital in the biotech industry to safeguard innovations and attract investment.
- Financing
-
Aspect: SBIR/SEED
Summary: Initial funding has been secured through grants, including from the National Science Foundation.
While grant funding provides a solid start, scaling operations and advancing clinical trials will require substantial additional capital.
- Regulatory
-
Aspect: Concept Stage
Summary: The company's therapeutics are in early development stages, with regulatory pathways yet to be navigated.
Navigating the complex regulatory environment for drug approval is a critical and time-consuming process that can impact time-to-market.
Opportunity Rollup
- Odds of Success
- 3.2
- Peak Market Share
- 4.55
- Segment CAGR
- 8.5%
- Market Segment
- Oncology Therapeutics
- Market Sub Segment
- Targeted Cancer Therapies
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.23 |
| 2 | 0.68 |
| 3 | 1.59 |
| 4 | 3.18 |
| 5 | 4.55 |
Key Takeaway
Window Therapeutics, Inc. is positioned in a competitive oncology market with a strong team and innovative technology, but faces significant technical and regulatory challenges ahead.